PWI, an innovative project, is developing a treatment based on GnRH (gonadotropin-releasing hormone) antagonists, repositioned in a clinical trial to treat the deleterious effects on reproduction and metabolism induced by polycystic ovary syndrome (PCOS). The aim is to revolutionise the management of PCOS patients, for whom no curative treatment is available.
PWI’s second objective is to conduct research and development activities to design new molecules with therapeutic potential, aimed at alleviating the symptoms of PCOS.
Would you like to edit the information on your profile page?
Oops! We could not locate your form.